Prevalence of elevated liver enzymes in adults with type 1 diabetes: A multicentre analysis of the German/Austrian DPV database

Diabetes, Obesity and Metabolism

Volumn 19, Issue 8, 2017, Pages 1171-1178

  Stadler, Marietta ^a,b   Bollow, Esther ^c,d   Fritsch, Maria ^e   Kerner, Wolfgang ^f   Schuetz Fuhrmann, Ingrid ^b   Krakow, Dietmar ^g   Merger, Sigrun ^h   Riedl, Michaela ^e   Jehle, Peter ⁱ   Holl, Reinhard W ^c,d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Hietzing Hospital Vienna   (Austria)

^c UNIVERSITY OF ULM   (Germany)

^d GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f Klinikgruppe Dr Guth GmbH and Co KG   (Germany)

^g Diabetesassistentin DDG   (Germany)

^h KLINIKUM COBURG   (Germany)

ⁱ Paul Gerhardt Diakonie Krankenhaus   (Germany)

Author keywords

cardiovascular; liver enzymes; type 1 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; LIVER ENZYME; BIOLOGICAL MARKER;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUSTRIA; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CLINICAL AUDIT; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DATA BASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSLIPIDEMIA; END STAGE RENAL DISEASE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GERMANY; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PATIENT CARE; PREVALENCE; REGISTER; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; COMPLICATION; FOLLOW UP; HYPERGLYCEMIA; HYPOGLYCEMIA; LIVER; LIVER FAILURE; NONALCOHOLIC FATTY LIVER; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RISK FACTOR;

ADULT; AUSTRIA; BIOMARKERS; COHORT STUDIES; COMORBIDITY; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; FOLLOW-UP STUDIES; GERMANY; HEPATIC INSUFFICIENCY; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; LIVER; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS;

EID: 85017409045     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12929     Document Type: Article

References (25)

1. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care. 2014;37(suppl 1):S14-S80.
2. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004;126:460-468.
3. Suh S, Kim KW. Diabetes and cancer: is diabetes causally related to cancer? Diabetes Obes Metab. 2011;35:193-198.
4. Williamson DF, Madans J, Anda RF, Kleinman JC, Giovino GA, Byers T. Smoking cessation and severity of weight gain in a national cohort. N Engl J Med. 1991;324:739-745.
5. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009;29:113-119.
6. Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care. 2007;30:2119-2121.
7. Merger SR, Kerner W, Stadler M, et al. Prevalence and comorbidities of double diabetes. Diabetes Res Clin Pract. 2016;119:48-56.
8. Schwab KO, Doerfer J, Hecker W, et al. Spectrum and prevalence of atherogenic risk factors in 27,358 children, adolescents, and young adults with type 1 diabetes: cross-sectional data from the German diabetes documentation and quality management system (DPV). Diabetes Care. 2006;29:218-225.
9. Vajro P, Paolella G, Maggiore G, Giordano G. Pediatric celiac disease, cryptogenic hypertransaminasemia, and autoimmune hepatitis. J Pediatr Gastroenterol Nutr. 2013;56:663-670.
10. Rosenbauer J, Dost A, Karges B, et al. Improved metabolic control in children and adolescents with type 1 diabetes: a trend analysis using prospective multicenter data from Germany and Austria. Diabetes Care. 2012;35:80-86.
11. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
12. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1-10.
13. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21:1983-1992.
14. Silveiro SP, Araujo GN, Ferreira MN, Souza FD, Yamaguchi HM, Camargo EG. Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation pronouncedly underestimates glomerular filtration rate in type 2 diabetes. Diabetes Care. 2011;34:2353-2355.
15. Radcke S, Dillon JF, Murray AL. A systematic review of the prevalence of mildly abnormal liver function tests and associated health outcomes. Eur J Gastroenterol Hepatol. 2015;27:1-7.
16. Mathiesen UL, Franzen LE, Fryden A, Foberg U, Bodemar G. The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. Scand J Gastroenterol. 1999;34:85-91.
17. Bonnet F, Ducluzeau PH, Gastaldelli A, et al. Liver enzymes are associated with hepatic insulin resistance, insulin secretion, and glucagon concentration in healthy men and women. Diabetes. 2011;60:1660-1667.
18. Mor A, Svensson E, Rungby J, et al. Modifiable clinical and lifestyle factors are associated with elevated alanine aminotransferase levels in newly diagnosed type 2 diabetes patients: results from the nationwide DD2 study. Diabetes Metab Res Rev. 2014;30:707-715.
19. Giandalia A, Romeo EL, Ruffo MC, et al. Clinical correlates of persistently elevated liver enzymes in type 2 diabetic outpatients. Prim Care Diabetes. 2017; 11: 226-232.
20. Bora K, Borah M, Chutia H, Nath CK, Das D, Ruram AA. Presence of concurrent derangements of liver function tests in type 2 diabetes and their relationship with glycemic status: a retrospective observational study from Meghalaya. J Lab Physicians. 2016;8:30-35.
21. West J, Brousil J, Gazis A, et al. Elevated serum alanine transaminase in patients with type 1 or type 2 diabetes mellitus. QJM. 2006;99:871-876.
22. Leeds JS, Forman EM, Morley S, Scott AR, Tesfaye S, Sanders DS. Abnormal liver function tests in patients with type 1 diabetes mellitus: prevalence, clinical correlations and underlying pathologies. Diabet Med. 2009;26:1235-1241.
23. Haring R, Wallaschofski H, Nauck M, Dorr M, Baumeister SE, Volzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology. 2009;50:1403-1411.
24. Targher G, Mantovani A, Pichiri I, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes. Diabetes Care. 2014;37:1729-1736.
25. Vendhan R, Amutha A, Anjana RM, Unnikrishnan R, Mohan V. Clinical profile of non alcoholic fatty liver disease among young patients with type 1 diabetes mellitus seen at a diabetes speciality centre in India. Endocr Pract. 2014;20:1-24.